


(39)

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

|   |  |   |
|---|--|---|
| (51) International Patent Classification <sup>6</sup> :<br><b>C07D 401/04, A61K 31/44</b>   | <b>A1</b>  | (11) International Publication Number: <b>WO 98/52941</b><br>(43) International Publication Date: 26 November 1998 (26.11.98) |
| <p>(21) International Application Number: PCT/US98/11684</p> <p>(22) International Filing Date: 22 May 1998 (22.05.98)</p> <p>(30) Priority Data:<br/>60/047,569 22 May 1997 (22.05.97) US</p> <p>(71) Applicant (for all designated States except US): G.D. SEARLE AND CO. [US/US]; P.O. Box 5110, Chicago, IL 60680 (US).</p> <p>(72) Inventors; and<br/>(75) Inventors/Applicants (for US only): HANSON, Gunnar, J. [US/US]; 7410 Keystone Avenue, Skokie, IL 60076 (US). LIAO, Shuyuan [CN/US]; 2N. 500 Diane Avenue, Glen Ellyn, IL 60137 (US).</p> <p>(74) Agents: ROEDEL, John, K., Jr. et al.; Senniger, Powers, Leavitt &amp; Roedel, 16th floor, One Metropolitan Square, St. Louis, MO 63102 (US).</p> | <p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p><b>Published</b><br/><i>With international search report.</i><br/><i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> |   |
| <p>(54) Title: PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS</p> <p>(57) Abstract<br/>A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula (I) wherein Q, R<sub>1</sub>, R<sub>2</sub>, R<sub>3</sub> and R<sub>4</sub> are as described in the specification.</p> <div style="text-align: right;">  <p>(1)</p> </div>   |  |   |